Apax Funds, CPPIB and PSP Investments agree to sell Acelity and its KCI Subsidiaries to 3M for $6.725 Billion


KCI is a leading global medical technology company focused on advanced wound care and specialty surgical applications. 

SAN ANTONIO and NEW YORK, May 2, 2019: A consortium comprised of funds advised by Apax Partners (the “Apax Funds”), together with Canada Pension Plan Investment Board (“CPPIB”) and the Public Sector Pension Investment Board (“PSP Investments”), today announced that it has entered into a definitive agreement to sell Acelity, Inc. and its KCI subsidiaries worldwide to 3M for approximately $6.725 billion. KCI markets a broad range of negative pressure wound therapy, specialty surgical and advanced wound dressing products in approximately 90 countries.

Since 2011, Apax Partners, CPPIB and PSP Investments worked closely with Acelity/KCI’s senior leadership team to transform the business into a leading global company focused on advanced wound care and specialty surgical solutions. The company’s strategic M&A program included targeted acquisitions, such as Systagenix, in 2013, and Crawford Healthcare, in 2018, and disposals of non-core businesses, such as the LifeCell business unit, which was sold for $2.9 billion in 2017, and the Therapeutic Support Systems (TSS) unit, which was sold in 2012. The company also has undertaken a range of organic growth initiatives including investments in R&D, clinical studies, and the expansion of its sales force.

The product offering includes the KCI-branded negative pressure wound therapy, advanced wound dressings, and negative pressure surgical incision management systems. The company’s industry-leading brands include V.A.C.® Therapy, PREVENA™ Therapy and PROMOGRAN PRISMA™ Matrix, as well as the iOn Digital Health platforms. Upon completion of the transaction, KCI will become an integral part of 3M’s Medical Solutions business, which applies 3M’s science to deliver safe and effective solutions that improve clinical outcomes and healthcare economics.

“Today, KCI embarks upon a new era in its long history as a pioneer in healthcare,” said R. Andrew Eckert, CEO of Acelity. “The combination of KCI with 3M will accelerate the reach of a business that is a leader in innovation, customer experience and clinical and economic evidence. Backed by the resources and expertise of 3M,KCIwill be able to offer clinicians and patients even more compelling solutions designed to speed healing and improve outcomes. I would like to thank Apax, CPPIB and PSP Investments for their close partnership and strategic direction over the years shaping KCI into a premier global advanced wound care company.”

Steven Dyson, Chairman of the Board of Acelity and Partner at Apax Partners, said, “We are proud of our close work with management to successfully transform KCI through a range of growth initiatives, including an M&A program, that enhanced the Company’s strategic direction. We believe the business will have a great future with 3M. Lastly, we are grateful for the opportunity to have joined in this highly successful investment with CPPIB and PSP, two long-standing investors in the Apax Funds.”

“CPPIB is pleased to have supported KCI’s delivery of medical devices and products that benefit millions of patients around the world. During our investment, the company helped restore lives with the launch of innovative solutions and expansion into new geographies,” said Ryan Selwood, Managing Director, Head of Direct Private Equity, CPPIB.

“We are proud to have supported KCI and its management team during its exciting transformation journey, in partnership with Apax and CPPIB,” said Simon Marc, Managing Director and Head of Private Equity, PSP Investments. “KCI has successfully invested into novel organic growth initiatives and we are confident about its continued growth prospects with 3M.”

The transaction will be effected through the sale of Acelity, Inc., a direct wholly-owned subsidiary of Acelity L.P. Inc., and is expected to close in the second half of 2019, subject to customary closing conditions and regulatory approvals.

JP Morgan and Goldman Sachs are acting as financial advisors to the consortium. Simpson Thacher & Bartlett LLP and Jackson Walker LLP are acting as legal advisors to the consortium.

About KCI, an Acelity Company
KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing.  Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.

About Apax Partners
Apax Partners is a leading global private equity advisory firm. Over its more than 40-year history, Apax Partners has raised and advised funds with aggregate commitments of over c.$50 billion. The Apax Funds invest in companies across four global sectors of Healthcare, Tech & Telco, Services, and Consumer. These funds provide long-term equity financing to build and strengthen world-class companies. For more information see: www.apax.com.

In Healthcare, the Apax Funds have invested c.$8 billion of equity across medical devices, pharmaceuticals, healthcare services and healthcare IT. Within the medical devices sub-sector, the Apax Healthcare team has partnered with a variety of businesses such as Mӧlnlycke, Vyaire Medical, Candela and Healthium to create strategic leaders in their space.

About Canada Pension Plan Investment Board
Canada Pension Plan Investment Board (CPPIB) is a professional investment management organization that invests the funds not needed by the Canada Pension Plan (CPP) to pay current benefits on behalf of 20 million contributors and beneficiaries. In order to build a diversified portfolio of CPP assets, CPPIB invests in public equities, private equities, real estate, infrastructure and fixed income instruments. Headquartered in Toronto, with offices in Hong Kong, London, Luxembourg, Mumbai, New York City, São Paulo and Sydney, CPPIB is governed and managed independently of the Canada Pension Plan and at arm’s length from governments. At December 31, 2018, the CPP Fund totalled C$368.5 billion.For more information about CPPIB, please visit www.cppib.com or follow us on LinkedInFacebook or Twitter.

About PSP Investments
The Public Sector Pension Investment Board (PSP Investments) is one of Canada’s largest pension investment managers with C$158.9 billion of net assets as of September 30, 2018. It manages a diversified global portfolio composed of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt. Established in 1999, PSP Investments manages net contributions to the pension funds of the federal Public Service, the Canadian Forces, the Royal Canadian Mounted Police and the Reserve Force. Headquartered in Ottawa, PSP Investments has its principal business office in Montréal and offices in New York, London and Hong Kong. For more information, visit investpsp.com or follow us on Twitter and LinkedIn.


Acelity Media Contacts:

Cheston Turbyfill,
VP, Corporate Communications Acelity
+1 312-952-0837

Acelity Investor Contacts:

David Clair, CFA,
Westwicke Partners

Apax Partners: 

Global Media: Andrew Kenny, Apax | +44 20 7 872 6371 | andrew.kenny@apax.com
USA Media: Todd Fogarty, Kekst | +1 212-521 4854 | todd.fogarty@kekst.com
UK Media: Matthew Goodman, Greenbrook | +44 20 7952 2000 | apax@greenbrookpr.com


Darryl Konynenbelt
Phone: +1 416-972-8389
Email: dkonynenbelt@cppib.com

PSP Investments:

Verena Garofalo
Phone: +1 (514) 218-3795
Email: media@investpsp.com

Search our news

Sector: All
Year: All

Global press contact

Andrew Kenny
t: +44 20 7872 6300
andrew.kenny@apax.comGreenbrook Communications
t: +44 20 7952 2000

Kate Albert
t: +44 20 7872 6300

See all Press contacts


Leading provider of therapies and products for the advanced wound care, tissue regeneration and therapeutic support system markets

Hits: 62

Categories: News


Gimv’s Life Sciences team establishes Advisory Board. Industry veterans Darnaud, Hirth, Kola, Kutay, LeBeaut and Moses joining.


29/04/2019 – 17:45 | Portfolio

Gimv announces it has created a Life Sciences Advisory Board. The new Advisory Board consists of 6 seasoned industry veterans with expertise in drug- and medtech development, company building and M&A. Michel Darnaud (former president cardiac surgery at LivaNova), Peter Hirth (former CEO Plexxikon), Ismail Kola (former CSO UCB), Kasim Kutay (CEO Novo Holdings), Alexandre LeBeaut (CSO Ipsen) and Edwin Moses (former CEO Ablynx) will assist the Gimv Life Sciences team with portfolio development, deal sourcing and assessing general industry trends.

Gimv has been active in Life Sciences since 1982, investing in more than 80 companies and generating a consistent top tier IRR. Successes include Ablynx, Plexxikon, Devgen, Covagen, Prosonix and Endosense. Embedded in the broader Health & Care platform, Gimv’s Life Sciences team is looking to invest in European early and late stage biotech and medtech companies in an amount of EUR 10-25 million per company, with funding coming from Gimv’s balance sheet in an evergreen setting. The Life Sciences team, including partners Karl Nägler, Bram Vanparys and Patrick Van Beneden, manages an active portfolio of 11 companies today and aims to expanding this to 15-20 companies over the coming years.

Karl Nägler: “Creating this advisory board highlights Gimv’s ambitions in the biotech and medtech field for the years to come. At Gimv we want to be partners for ambitious entrepreneurs. By establishing our Advisory Board we broaden the network and add value to our portfolio.”

Bram Vanparys adds “We are very happy to establish a close collaboration with these renowned and successful professionals, each of whom has done great things in our industry. With this collaboration, we can further increase Gimv’s value to patients, portfolio companies and shareholders.”

Hits: 4

Categories: News


Montagu Private Equity announces the completion of the sale of D.O.R.C.


Montagu Private Equity (“Montagu”), a leading European private equity firm, today announced the completion of the sale of Dutch Ophthalmic Research Center (“D.O.R.C.” or “the Company”), a leading provider of innovative instruments and equipment for ophthalmic surgery, to Eurazeo Capital. Terms of the transaction are not being disclosed.

Established in 1983, D.O.R.C. is a leading provider of innovative instruments and equipment for ophthalmic surgery. The product range includes high precision disposable and re-usable instruments, surgical liquids and surgical machinery that is used for vitreoretinal and cataract procedures. Headquartered in Zuidland, the Netherlands, D.O.R.C. serves a global customer base including surgical centres, hospitals and physicians across the US, Europe, the mid-East, Asia and South America. The Company has more than 500 employees worldwide.


The transaction was first announced on 13 March 2019 and has now received clearance from relevant competition and regulatory authorities.


Montagu was advised by HSBC and RBC Capital Markets.

Hits: 5

Categories: News


EURAZEO CAPITAL completes its acquisition of DORC


Paris, April 25, 2019 – Eurazeo Capital announces the completion of the acquisition of DORC (Dutch
Ophthalmic Research Center), one of the global leading specialists of vitreoretinal surgery. Headquartered
in the Netherlands, DORC designs, manufactures and distributes ophthalmic surgery equipment,
consumables and instruments worldwide. DORC enjoys strong market positions notably in Western
Europe, and more recently in the US.
DORC has a strong brand recognition and is widely recognized for its innovation track record. It has
delivered a consistently strong financial performance, supported by growing global ophthalmic surgery

In 2018, DORC generated revenues of €125 million, with an average annual growth rate of 9% over the
past 3 years. The transaction consists in the acquisition of 100% of the share capital of DORC and will be
the fifth investment of Eurazeo Capital IV. The company is valued at c. €430 million (enterprise value), of
which c. €300 million equity funded by Eurazeo and its affiliates.

About Eurazeo
o Eurazeo is a leading global investment company, with a diversified portfolio of €17 billion in assets under
management, including nearly €11 billion from third parties, invested in over 300 companies. With its considerable
private equity, venture capital, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies
of all sizes, supporting their development through the commitment of its 235 professionals and by offering deep sector
expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid
institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment
horizon enable Eurazeo to support its companies over the long term.
Eurazeo has offices in Paris, New York, Sao Paulo, Buenos Aires, Shanghai, London, Luxembourg, Frankfurt and
o Eurazeo is listed on Euronext Paris.
o ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

Hits: 5

Categories: News


ACTIVA CAPITAL acquires MEDISYS, software publisher in the medico-social sector, alongside entrepeneur Guillaume Bouillot

Activa Capital

Activa Capital has acquired a majority position in Medisys, together with Turenne Santé, the entrepreneur
and new CEO Guillaume Bouillot and the management team. Bernard Chevalier, founder, is supporting the
operation and remains a shareholder.
Medisys is a leading software publisher in the home-care field and for institutions specialized in dependent

After nearly 30 years at the head of the company based in Aix-en-Provence and created in 1991, its founder
Bernard Chevalier hands over the management to Guillaume Bouillot, a software entrepreneur.
The new management team will build on values that have made the company successful while providing
the means to accelerate the digitalization of personal services. The challenge is to support the
transformation of organizations that bring together care institutions, home support, medical/nursing
services and aids to daily life. Medisys’ development is based on its recognized expertise in the care of
dependent persons and on its technological innovations making it possible to streamline the operators’
organization and secure the patient follow-up. The company also intends to intensify the deployment of
traceability systems for hygiene and cleaning services in sensitive environments, particularly in the medical
sector, with its Mobiserv solution.
Thanks to 17 years of experience between the creation and sale of Eudonet (a publisher of CRM solutions),
Guillaume Bouillot brings a new energy to the company with a desire to accelerate by fostering links with
customers and the ecosystem.
Activa Capital and Turenne Santé will enable Medisys to strengthen its positions through strategic
acquisitions to complete its offer.

With this transaction, Activa Capital is making the 9th investment of its latest fund, Activa Capital Fund III.
Guillaume Bouillot, President of Medisys Holding, said: “I was very impressed by Activa Capital’s unique
ability to support entrepreneurs and bring its skills and energy to bear on their ambitions. The association
with the sector specialist Turenne Santé is a key asset for this transition from one entrepreneur to another
in a consolidating sector”.

Bernard Chevalier, Founder of Medisys, added: “This is a new momentum for Medisys, which has the solid
fundamentals to pursue and expand its rapid development and satisfy our most demanding clients in the
medico-social sector”.

Christophe Parier and Alexandre Masson, Partners of Activa Capital, completed: “We were impressed by
Medisys’ history and positioning. The arrival of Guillaume Bouillot will enable the company to carry out its
ambitious development projects. This acquisition is in line with Activa Capital’s strategy of investing in
companies that are at a turning point in their growth to help them accelerate their development”.

Mounia Chaoui, Associate Director, Turenne Santé stated: “We are delighted to support Guillaume Bouillot
and the Medisys teams in the takeover of the group, in partnership with Activa Capital. Medisys has
developed a remarkable offer that facilitates the development of home services, at the heart of new
healthcare policies that we are addressing with Capital Santé 2”.

Corporate lawyer: Allen Overy (Raphaël Bloch)

Activa Capital: Christophe Parier, Alexandre Masson, Frédéric Singer, Elliot Thiéblin
Turenne Santé: Mounia Chaoui, Grégory Dupas
Financial Due Diligence: PwC (David Willems, Pierre-Mikhaël, Kévin Barrier)
Strategic Due Diligence: PMSI (Remi de Guilhermier, Florence Royer, Lucinda Nicholson)
Social and legal Due Diligence: Hogan Lovells (Stéphane Huten, Paul Leroy, Alexandre Jeannerot)
M&A advisor: Bryan Garnier (Thibaut De Smedt, Pierre Lafitte, Alexandre Brestin)
Corporate lawyers: Hogan Lovells (Stéphane Huten, Paul Leroy, Alexandre Jeannerot), Paul Hastings
(Sébastien Crepy)
Financing lawyer: Hogan Lovells (Alexander Premont, Luc Bontoux, Adrien Gaudron)

Vendor Due Diligence: Exelmans (Stéphane Dahan, Manuel Manas, Matthieu Réglade, Philippe Pelet)
M&A advisor: Edmond de Rothschild Corporate Finance (Philippe Duval, Marguerite Mell, Lucrèce
d’Assignies, Aurélien Rivière)
Corporate lawyer: Lamartine Conseil (Vincent Libaud)
Senior financing
Senior debt: Crédit du Nord (Bertrand Descours, Amandine Proux), Crédit Agricole Provence Alpes Côte
d’Azur (Christophe Lejeune, Violaine Mahier), BNP Paribas (Mathias Ronzeaud)

About Activa Capital
Activa Capital is an independent private equity company, owned by its partners, characterized by a proactive
strategy of supporting growth (organic and external). It currently manages more than €500 million on behalf
of institutional investors by investing in French SMEs and Mid-Caps with high growth potential and an
enterprise value ranging between €20 million and €100 million. Activa Capital supports its portfolio
companies to accelerate their development and international presence, often through active build-up
To learn more about Activa Capital, visit activacapital.com

About Turenne Capital Group
With more than €220 million under management, including more than €100 million for the FPCI Capital
Santé 2, Turenne Santé supports healthcare companies in their development and transmission challenges.

As an independent private equity player in France, the Turenne Capital group manages more than €1 billion.
Its teams, composed of 55 professionals, including 38 investors, based in Paris, Lille, Lyon, Marseille and
Metz, support more than 250 companies employing more than 23,000 people in the health, hospitality,
new technology, distribution and innovative services sectors.
To learn more about Turenne Capital, visit www.turennecapital.com

Press contacts
Christophe Parier Alexandre Masson Christelle Piatto
Partner Partner Communications Manager
+33 1 43 12 50 12 +33 1 43 12 50 12 +33 1 43 12 50 12
christophe.parier@activacapital.com alexandre.masson@activacapital.com christelle.piatto@activacapital.com
Mounia Chaoui Josepha Montana
Partner Communications Manager
+33 1 53 43 03 03 +33 1 53 43 03 03
mchaoui@turennecapital.com jmontana@turennecapital.com

Hits: 24

Everstone Group to acquire controlling stake in Sahyadri Hospitals


Mumbai, April 07, 2019 – The Everstone Group(Everstone), has signed an agreement to acquire a controlling stake in Sahyadri Hospitals Limited(Sahyadri), the largest hospital chain in Maharashtra. The combination of primary and secondary capital outlay is expected to increase the bed-count significantly in next five years.

Founded in 1994, Pune headquartered Sahyadri Hospitals currently operates 5 tertiary care and 3 secondary care hospitals with 750 beds across Pune (Deccan Gymkhana, Nagar Road, Kothrud, Bibwewadi, Kasba Peth and Hadapsar), Nashik and Karad areas. Sahyadri has more than 1000 clinicians along with 2300 supporting staff providing latest medical services.

Sameer Sain, CEO, Everstone Group, said, “Sahyadri Hospitals is a reputed name for quality healthcare and will act as the anchor asset of our healthcare delivery platform. Everstone will leverage its’ significant healthcare expertise and experience to grow the overall business. We look forward to working closely with our partners and stakeholders.”

Commenting on the investment, Dr. Charudutt Apte, Founder, Chairman and MD, Sahyadri Hospitals said, “We are excited about this partnership and the value Everstone Group brings. Sahyadri Hospitals looks forward to the next phase of growth with the support of the experienced team at Everstone.”

According to industry estimates, private secondary and tertiary healthcare delivery in India is expected to grow from USD 42 bn in 2018 to USD 65 bn by 2022 at a CAGR of ~12%. This investment will help Sahyadri to cement its position as the leading healthcare chain in Maharashtra.

Everstone is one of the largest India and South East Asia focused healthcare investor specializing in rolling up assets within their platforms. In 2015, Everstone successfully exited Global Hospitals, a large multi-specialty tertiary hospital chain, generating strong returns. Everstone’s healthcare portfolio includes controlling stakes in domestic pharma distribution platform, Ascent Health; South East Asia based diagnostic device platform Everlife and an investment in one of the largest nutraceutical ingredient business, OmniActive. Everstone recently announced its successful exit from Rubicon Research (Rubicon) generating returns of 4.5x.

About Everstone Group
Everstone is a premier investment group focused on India and South East Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com

About Sahyadri Hospitals
Sahyadri Hospitals is the largest chain of hospitals in Maharashtra with 8 hospitals across three cities of Pune, Nashik and Karad. The hospital chain has over 900 Beds, 1,200 Clinicians and 2,300 Support Staff providing round the clock healthcare.
To know more: www.sahyadrihospital.com

Hits: 1

Categories: News


Carlyle Cardinal Ireland Invests in Sports Surgery Clinic


Specialist Orthopaedic & Sports Medicine Hospital To Focus on Continued Growth of Patient Services and Facilities

Dublin, Ireland – Carlyle Cardinal Ireland (CCI), the private equity fund established by The Carlyle Group (NASDAQ: CG) and Cardinal Capital Group, has agreed to an investment in Sports Surgery Clinic (SSC), a private hospital specialising in orthopaedic surgery, spinal surgery and sports medicine.  The investment, terms of which are not being disclosed, is expected to complete in the coming months.

SSC, located in Santry, Dublin, is a state-of-the-art private hospital dedicated to orthopaedics and sports medicines.  Launched in 2007, SSC introduced world-class facilities and treatment into Ireland for orthopaedic joint-replacement surgery, spinal surgery and sports medicine.  The hospital has quickly grown to become a premier provider of both sports medicine and orthopaedic joint-replacement surgery in Ireland with a reputation for leading-edge innovation and highest standards of patient care.

Facilities at SSC include five ultra-clean-air operating theatres dedicated to orthopaedic and spinal surgical procedures, a diagnostic-imaging service including two 3-Tesla MRI scanners and a 64-slice CT scanner, and an expansive physiotherapy and rehabilitation department incorporating wellness and health-screening facilities.  A recently developed sports medicine-dedicated laboratory provides performance rehabilitation, running clinics, fitness testing and physiotherapy services.  Currently employing over 300 people, SSC’s capacity comprises 63 in-patient beds, 26 day-care beds and 21 on-site consultancy suites.

Jonathan Cosgrave, Managing Director, The Carlyle Group and John Dolan, Managing Director, Cardinal Capital Group, will join the board of directors of SSC upon completion of the investment.

Dr. Josh Keaveny, Chief Executive, SSC said: “With our patient-focused model of care we are continuously exploring the science and medicine related to sports injuries, athletic performance, joint replacement and spinal injury.  We aim to keep people of all ages fit and active.  The investment from CCI allows us to accelerate our growth and we plan to begin work in the near future on expanding the hospital.  This expansion will significantly increase our capacity which will enable us to treat more patients.”

John Dolan, Managing Director, Cardinal Capital Group, said: “CCI’s financial backing of SSC’s expansion plan will add two additional theatres, which will increase surgical capacity by 40%, meaning more of the population can readily access the hospital’s leading facilities and consultants.  With an increased focus on exercise and wellness, more and more people are looking for restorative procedures, particularly knee and hip replacements, and shoulder surgery.  SSC’s specialist orthopaedic and rehabilitation expertise has allowed it establish a national reputation for treating injuries in both professional and amateur athletes, and members of the wider population.”

Jonathan Cosgrave, Managing Director, The Carlyle Group, said: “SSC is CCI’s second healthcare sector investment and we are excited to be partnering with such a high quality, ambitious management team and group of staff.  Planned increases to SSC’s operating capacity will expand SSC’s workforce and we look forward to adding new consultants, nurses and other healthcare professionals to the SSC team.  The Irish population aged over 65 years is forecast to increase 45% by 2030 driving a significant increase in annual demand for hip and knee joint replacements, and SSC’s management team and staff are well positioned to service this growing patient demand.”

CCI has been an active growth investor in the Irish market since 2014.  SSC is the fund’s tenth investment and the fund continues to explore other investment opportunities.  Current fund investments include The AA Ireland, Payzone, Carroll Cuisine, Learning Pool, McCauley Pharmacy Group, Abtran and Millicent Pharma.  CCI previously invested in Lily O’Brien’s and General Secure Logistics Services (GSLS), both high-growth companies run by first-class management teams, each of which underwent an exit process in 2018.

CCI’s investment in SSC is subject to approval from the Competition and Consumer Protection Commission (CCPC).

* * * * *

Press Contacts:

The Carlyle Group
Laurie Mannix, MKC Communications
Tel: +353 (0)1 703 8620 Mob: +353 (0)86 814 3710 laurie@mkc.ie

Cardinal Capital Group
Tom McEnaney, McEnaney Media
Tel: +353 (0)87 2222 666 tom@tommcenaney.com

About Sports Surgery Clinic (SSC)

SSC’s goal is dedicated to delivering the highest standards of diagnosis, prehabilitation, treatment, rehabilitation and full recovery care for its patients.  The hospital aims to provide an exceptional working environment for staff with a focus on continuous education and quality improvement to support excellence in patient care.

SSC’s facilities are built with optimised patient outcomes in mind.  They include five ultra clean-air operating theatres, a world-class diagnostic imaging department, an expansive physiotherapy department, a wellness and health screening facility, as well as dedicated research laboratories which highlight the commitment that SSC places on promoting future breakthroughs in orthopaedic surgery.

SSC offers patients all the advantages of the newest technologies, including 21 on-site consulting rooms that ensure rapid and smooth access to consultant expertise on a continuous basis.  The hospital houses some of the world’s most advanced radiology equipment including two 3-Tesla MRI scanners and a 64-slice CT scanner, both of which yield superior image quality and resolution, particularly in the diagnosis of soft tissue and orthopaedic injuries.

Patient comfort is at the heart of the service provided by the SSC.  In total, the clinic offers 63 in-patient beds in addition to 26 day-care beds.  Each patient room has its own ensuite bathroom with shower, and entertainment centre incorporating internet, radio and telephone access along with both clinic and treatment information.

About Carlyle Cardinal Ireland

Carlyle Cardinal Ireland is a joint venture between The Carlyle Group (NASDAQ: CG) and Cardinal Capital Group.  The €292 million private equity fund is focused on growth capital and buyout investment opportunities across the island of Ireland.

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $216 billion of assets under management as of December 31, 2018, Carlyle’s purpose is to invest wisely and create value on behalf of our investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,650 people in 31 offices across six continents.

The Carlyle Group is a seasoned investor in the hospital sector.  Notable hospital investments include Schoen Klinik (Germany  17 hospitals), Rede D’Or São Luiz (Brazil  38 hospitals), Healthscope (Australia  45 hospitals), Medical Park (Turkey – 18 hospitals) and Medanta (India  3 hospitals, 1 Day Care Facility and 2 new hospitals under construction).

Web: www.carlyle.com
Videos: www.youtube.com/onecarlyle
Tweets: www.twitter.com/onecarlyle
Podcasts: www.carlyle.com/about-carlyle/market-commentary

About Cardinal Capital Group

Cardinal Capital Group is Ireland’s leading provider of alternative capital, directing private-equity capital, mezzanine finance and alternative lending to a broad range of sectors in the Irish market.  Cardinal invests its own capital alongside institutional funders to support entrepreneurs and corporate management teams as well as real-estate investors and developers.

Web: www.cardinalcapitalgroup.com

Hits: 16

Categories: News


European Sperm Bank is entering a partnership with Axcel


One of the Europes leading sperm banks, European Sperm Bank, has today entered into a new partnership with Axcel, which has now taken over the majority of shares. The partnership is built on a life-affirming vision and an ambitious plan to give even more Danish and foreign women and couples the possibility to have children. They plan is to expand even further by developing the existing business, expanding to new markets and expand the bank’s services

Since 2004, the European Sperm Bank has helped women and couples fulfill the dream of having a child. The result is more than 34.000 children among more than 25.000 families. Last year alone, the company had customers from over 70 different countries. European Sperm Bank is based in Denmark but has set up clinics for local recruitment in Germany and England.

We had a healthy development where we most importantly had a part in creating a lot of happiness among women and couples, who around the world needed our help to have children. In the new partnership with Axcel, we will not only continue our good deeds but together we want to boost development, innovation and expansion, which we are now looking forward to, “says Annemette Arndal-Lauritzen, who has been CEO of European Sperm Bank since 2013.

Today, Axcel owns two thirds of European Sperm Bank. Founder and previous majority shareholder, Peter Bower, the executive branch and co-workers will own remaining third of the shares. Annemette Arndal-Lauritzen will continue as CEO and the about 80 current employees can look forward to new colleagues.

Axcel has for several years followed European Sperm Bank and is impressed by the company’s customer-related services, their relentless focus on high quality, regulative processes and ethical standards. Therefore, we are looking forward to now supporting Annemette and her team in the further expansion in existing European markets and new ones,” says Thomas Blomqvist, Partner and Head of Investments at Axcel.

Global demand

Both in Germany and England, the sperm bank is experiencing an increase in demand for local donors. Therefore, in both countries there will be an increased focus on recruitment of local donors through the sperm bank’s local recruitment clinics in Hamburg and London.

Globally, we are experiencing an increasing demand for donors who represent a broad segment of the world’s population. We would like to contribute to giving as many people as possible the child they wish for,“ says Annemette Arndal-Lauritzen and continues:

Together with the new owners, the goal is to continue the European expansion and at the same time look at the possibilities of opening up outside of Europe. We will also focus on increased digitalization, and we will also look more into product-related innovation, which both in Denmark and globally will create synergy to our current supply.

For further information, please contact

Julie Paulli Budtz, Head of Communication & Brand, European Sperm Bank

Mobile: +45 8177 5500

E-mail: jpb@europeanspermbank.com

Thomas Blomqvist, Partner and Head of Investments, Axcel

Mobil: +46 709 221049

About European Sperm Bank

European Sperm Bank was founded in 2004. Today, the Sperm Bank has about 80 employees spread across offices and clinics in Denmark (Copenhagen, Lyngby and Aarhus), England (London) and Germany (Hamburg).

European Sperm Bank is globally a market leader within its field and has since the beginning helped couples and women across 99 countries. In total, more than 34.000 children have been delivered among 25.000 families (women and couples), and in 2018 alone they had customers from 70 different countries. European Sperm Bank’s focus on security, safety and quality makes the sperm bank a preferred business partner on a global scale.

Read more here

Om Axcel

Founded in 1994, Axcel is a Nordic private equity firm focusing on mid-market companies and has a broad base of both Nordic and international investors. Axcel has raised five funds with total committed capital of just over EUR 2.0 billion. These funds have made 53 platform investments, with almost 100 major add-on investments. 41 businesses have been sold or listed. Axcel currently owns 12 companies with combined annual revenue of more than EUR 1.4 billion and more than 6,300 employees. European Sperm Bank is Axcel V’s seventh investment.

Hits: 2

Categories: News


3i-backed Ponroy accelerates its international expansion with the acquisition of Pasquali Healthcare


3i Group plc (“3i”) today announces that Ponroy Santé Group (“Ponroy”), a leading European company in the natural consumer healthcare industry in which 3i invested in January 2017 together with co-investor Cathay Capital and management, is acquiring Pasquali Healthcare, a leading pharmaceutical company in Italy.

Founded in 1999 and headquartered in Florence, Pasquali Healthcare develops and commercialises OTC products in the Italian pharmacy market. Its portfolio of products includes medicated skincare and natural food supplements. Its main brand, Dermovitamina (c. 60% of total sales), is the leading and most innovative medicated skincare brand in Italy, offering a wide portfolio of products for all skin disorders and benefiting from strong brand awareness.

Pasquali Healthcare is an innovative and fast-growing company; it has enjoyed double-digit growth over the last 5 years and generated €23m of sales in 2018.

This is the third acquisition made by Ponroy with the support of 3i, after the acquisitions of Ersa (Aragan and Synactifs brands) in September 2017 and Densmore (Suveal Duo and Memoptic brands) in July 2018. Following these acquisitions, Ponroy is now the third largest player in the French food supplement pharmacy channel and aims to replicate its successful business model across Europe.

The acquisition of Pasquali Healthcare adds a new product line to Ponroy’s offering in the pharmacy channel and will significantly strengthen Ponroy’s presence in Italy, the largest market for food supplements in Europe, where the Group currently operates through a subsidiary distributing the Vitarmonyl and Biopha Nature brands. Pasquali Healthcare will bring its unique expertise in the Italian pharmacy channel, thanks to its nation-wide distribution through 7,000 pharmacies and several distributors and will continue growing in Italy but also abroad thanks to Ponroy’s international network and digital capabilities.

Costantino Pasquali will continue to be CEO of Pasquali Healthcare and will lead the development of Ponroy in the Italian pharmacy channel.

Philippe Charrier, President and CEO of Ponroy, commented:

“Costantino Pasquali is a first-class entrepreneur and we share the same values and principles. He has built a strong brand with Dermovitamina, which we want to transform into an international brand. Our product portfolios are highly complementary and the expertise of Pasquali Healthcare in the pharmacy channel will be key for both our development in Italy and internationally. We look forward to working with Costantino Pasquali and his team.”

Costantino Pasquali, CEO of Pasquali Healthcare, added:

“I am delighted to see Pasquali Healthcare joining forces with Ponroy to initiate a new phase of its development. We will accelerate the international expansion of the Dermovitamina brand thanks to Ponroy’s international network, while we will also benefit from new and exciting opportunities granted by the product offering of the combined group.”

Rémi Carnimolla, Partner and Managing Director, 3i France, and Guillaume Basquin, Director, 3i France commented:

“This is a strategic acquisition for Ponroy and fully in line with 3i’s buy-and-build strategy of helping its portfolio companies to expand internationally. After two value-creative acquisitions in France, Pasquali Healthcare will support the development of Ponroy in the attractive Italian market.”

The acquisition is expected to close in Q2 2019.

Deal team
3i: Rémi Carnimolla, Guillaume Basquin, Jérémy Nakache, Marc Ohayon
Ponroy: Philippe Charrier, Matthieu Mourette

Advisors to Ponroy 
M&A: Marco Termini
Legal: Legance (Francesco Florio, Flavia Carmina, Pietro La Placa)
Finance: PWC (Giovanni Tinuper, Stella Guarino) Strategy: Roland Berger (Patrick Biecheler, Pierre-Antoine Bodin, Eléonore Moreau)

Advisors to Pasquali Healthcare
M&A: Azimut Global Counseling (Giancarlo Maestrini, Massimo Polidori)
Legal: Gatti Pavesi Bianchi (Stefano Valerio, Amélie Gillet, Tommaso Carcaterra)

Hits: 8

Categories: News


Klingel acquires MedTech companies Bächler Feintech and Gehring Cut with the support of IK Investment Partners


Klingel medical metal group (“Klingel”), owned by the IK VIII Fund, announce that it has completed the acquisitions of Bächler Feintech AG (“Bächler”) and Gehring Cut AG (“Gehring”). Both companies are leading manufacturers of high-precision surgical instruments for the global MedTech market.

Bächler was founded in 1964 and employs 140 people at the production site in Hölstein, Switzerland, where state-of-the-art machinery and industry-leading quality management are established.

Gehring was founded in 1948 and employs 75 people at the production site in Matzingen, Switzerland, where similar to Bächler, a state-of-the-art machine park and industry-leading quality management are established.

Through these acquisitions, Klingel strengthens its position as the leading pan-European MedTech CMO for complex components and instruments. The extended platform enables the combined group to provide its broad global customer base with a more flexible service to meet their customers’ high quality requirements and to serve their ever-increasing demands.

“With Bächler and Gehring we have found the perfect complements to our MedTech platform. Through the acquisitions, we are gaining additional blue-chip customers, manufacturing capabilities and valuable expertise for our group, enabling us to create real value-add for our customers. In addition, we have found strong partners in the management teams of Bächler and Gehring and look forward to our next phase of growth as a larger pan-European group”, said Ralf Petrawitz, CEO of Klingel.

For further questions, please contact:

KLINGEL medical metal
Ralf Petrawitz, CEO
Phone: +49 7231 6519 0

IK Investment Partners
Anders Petersson, Partner
Phone: +49 40 369 8850

Mikaela Murekian, Director Communications & ESG
Phone: +44 77 87 573 566

About KLINGEL medical metal
For more than 30 years, KLINGEL medical metal GmbH has been one of the leading European precision technology companies with a strategic focus on medical technology industries. Employing over 300 people, KLINGEL medical metal GmbH specialises in the precision processing of materials with low machinability, such as titanium and high-grade stainless steel. KLINGEL offers unrivalled technical quality and aesthetic perfection. For more information, visit www.klingel-med.de

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

Press Service

Hits: 10

Categories: News